Terms ending in 2033
Every in-force patent on Sanbio, Inc.'s record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,245,286 | Methods and Compositions for Modulating Angiogenesis and Vasculogenesis In force · Medium confidence | Sanbio, Inc. | In force | Medium confidence | |
| US 9,326,999 | Methods and Compositions for Treatment of Retinal Degeneration In force · High confidence | Sanbio, Inc. | In force | High confidence | |
| US 9,828,593 | Methods and Compositions for Treatment of Traumatic Brain Injury and for Modulation of Migration of Neurogenic Cells In force · High confidence | University of South Florida | In force | High confidence | |
| US 9,855,299 | Methods and Compositions for Treatment of Retinal Degeneration In force · High confidence | Sanbio, Inc. | In force | High confidence | |
| US 10,626,389 | Methods and Compositions for Modulation of Migration of Neurogenic Cells In force · High confidence | University of South Florida | In force | High confidence | |
| US 10,702,554 | Extracellular Matrix from Pluripotent Cells In force · High confidence | Sanbio, Inc. | In force | High confidence | |
| US 12,171,787 | Methods and Compositions for Modulating Angiogenesis and Vasculogenesis In force · High confidence | Sanbio, Inc. | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
5 of these are in force and held by Sanbio, Inc..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.